Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB204 in acne vulgaris
NCT02672332Phase 3Completed
- Sponsor
- Novan
- Start
- Feb 2016
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing SB204 4% with Vehicle Gel (2 arms). Primary endpoints: Absolute Change From Baseline in Inflammatory Lesion Counts at 12 weeks, Absolute Change From Baseline in Non-inflammatory Lesion Counts at 12 weeks and 1 more. Started Feb 2016; status: completed.
02
Drugs
berdazimer
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02672332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672332.